VIP Peptide

VIP, or vasoactive intestinal peptide, is a 28 amino acid signalling peptide that acts on the VPAC1 and VPAC2 receptors and is cleared from circulation with a half-life of roughly two minutes. Its synthetic form aviptadil has carried orphan designations since 2003 without producing a marketed systemic medicine, its phase 3 result came back flat, and the only approved product containing it is a locally injected urology combination.

Naming a molecule after where you found it is risky, because molecules move.

Vasoactive Intestinal Peptide was isolated from pig intestine in 1970. Then it turned up in the lungs.

The brain, the pancreas, immune cells. The list kept going.

Twenty-eight residues, working through two receptors spread across half the body's tissues.

That spread is the whole character of this molecule: genuinely important, and genuinely everywhere.

Which sounds like an asset right up until you try to aim it.

Here's the problem with signals the body uses everywhere.

A molecule that relaxes airway muscle also does things to blood vessels, gut, immune cells and neurons, because those tissues all read the same channel.

Every tissue with the receptor hears it. The interesting research question was always whether you could get the announcement to only the department you meant.

Add the standard peptide problem, a half-life measured in minutes, and the delivery challenge stacks on top of the targeting one.

Here's the honest part. Physiological importance and pharmaceutical usefulness are cousins, not twins.

This molecule is unambiguously the first. The 461-patient trial in the next section is what happened when somebody tested the second.

One number carries this file: 461.

That is the patient count of the phase 3 trial of a VIP-based drug candidate that was stopped for futility, which is trial language for the data showing the answer would be no, so continuing was pointless.

A futility stop is arguably more informative than most positive small studies, because it had the statistical power to mean something.

Basic VIP biology remains foundational and widely cited. The drug-development thread ended where the data ended it.

A genuinely important molecule whose big test came back negative. Both halves belong on the page, and most pages selling it only carry the first.

Same day out of British Columbia. Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.

Then into the fridge. Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.

The half-life is the whole story. Two minutes in plasma. Every trial that produced a real result used continuous infusion or direct local injection. That is a fact about the molecule, not a formulation problem waiting to be solved by a vial.